Reyvow is a drug owned by Eli Lilly And Co. It is protected by 5 US drug patents filed from 2020 to 2025. Out of these, 4 drug patents are active and 1 has expired. Reyvow's patents have been open to challenges since 01 February, 2024. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 06, 2040. Details of Reyvow's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11053214 | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(12 years from now) | Active |
| US7423050 | Pyridinoylpiperidines as 5-HT1F agonists |
Feb, 2028
(2 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12071423 | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate |
Jul, 2040
(14 years from now) | Active |
| US12257246 | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide |
Jul, 2030
(4 years from now) | Active |
| US8748459 | Pyridinoylpiperidines as 5-HT1F agonists |
Mar, 2023
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Reyvow's patents.
Latest Legal Activities on Reyvow's Patents
Given below is the list of recent legal activities going on the following patents of Reyvow.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Certificate
Critical | 11 Aug, 2023 | US7423050 |
| Electronic Review
Critical | 16 May, 2023 | US7423050 |
| FDA Final Eligibility Letter
Critical | 26 Apr, 2023 | US7423050 |
| PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED
Critical | 19 Apr, 2023 | US7423050 |
| Interim Patent Term Extension Granted
Critical | 27 Mar, 2023 | US7423050 |
| Terminal Disclaimer Filed
Critical | 27 Mar, 2023 | US7423050 |
| PTE Interim Patent Extension filed
Critical | 23 Mar, 2023 | US7423050 |
| transaction for FDA Determination of Regulatory Review Period | 13 Sep, 2022 | US7423050 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 Sep, 2022 | US7423050 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Nov, 2021 | US8748459 |
FDA has granted several exclusivities to Reyvow. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Reyvow, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Reyvow.
Exclusivity Information
Reyvow holds 1 exclusivities. All of its exclusivities have expired in 2025. Details of Reyvow's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2025 |
US patents provide insights into the exclusivity only within the United States, but
Reyvow is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Reyvow's family patents as well as insights into
ongoing legal events
on those patents.
Reyvow's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Reyvow's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 06, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Reyvow Generics:
There are no approved generic versions for Reyvow as of now.
Alternative Brands for Reyvow
Reyvow which is used for managing acute migraine attacks., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Abbvie |
| |||
| Currax |
| |||
| Scilex Pharms |
| |||
| Tonix Meds |
| |||
About Reyvow
Reyvow is a drug owned by Eli Lilly And Co. It is used for managing acute migraine attacks. Reyvow uses Lasmiditan Succinate as an active ingredient. Reyvow was launched by Eli Lilly And Co in 2020.
Approval Date:
Reyvow was approved by FDA for market use on 31 January, 2020.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Reyvow is 31 January, 2020, its NCE-1 date is estimated to be 01 February, 2024.
Active Ingredient:
Reyvow uses Lasmiditan Succinate as the active ingredient. Check out other Drugs and Companies using Lasmiditan Succinate ingredient
Treatment:
Reyvow is used for managing acute migraine attacks.
Dosage:
Reyvow is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 100MG BASE | TABLET | Prescription | ORAL |
| EQ 50MG BASE | TABLET | Prescription | ORAL |
| EQ 200MG BASE | TABLET | Discontinued | ORAL |